Home | Welcome to Contract Pharma   
Last Updated Thursday, July 24 2014
Print RSS Feed

Prothena, Roche Initiate Development Pact



By Kristin Brooks



Published January 23, 2014
Related Searches: Development Preclinical Phase I
Prothena Corp., under its license, development, and commercialization agreement with Roche, will receive the $30 million upfront payment from Roche, triggered by the expiration of the Hart-Scott-Rodino waiting period. The companies entered the worldwide collaboration in December 2013 to develop and commercialize antibodies that target α-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease, which is currently in preclinical development and is expected to enter Phase I trials this year.
 
"This initial payment of $30 million marks the beginning of Prothena's collaboration with Roche, to co-develop and potentially co-commercialize PRX002," said Dale Schenk, Ph.D., president and chief executive officer of Prothena. "Prothena and Roche aim to develop PRX002 as a disease modifying treatment for Parkinson's disease and potentially other synucleinopathies, and so we very much look forward to working with Roche to initiate Phase I studies for PRX002 in the coming months.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On